Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
129.3 USD | +2.90% | +6.66% | +29.84% |
03:17pm | Investors need more than PPI to make up their minds | |
11:26am | ANALYST RECOMMENDATIONS : Nike, Roblox, Starbucks, Walmart, Deckers Outdoor... |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.84% | 48.16B | B- | ||
+0.03% | 41.73B | B | ||
+43.29% | 41.03B | A | ||
-5.31% | 28.77B | C | ||
+10.82% | 25.59B | B- | ||
-22.02% | 18.96B | B | ||
+9.43% | 12.92B | B+ | ||
+28.51% | 12.03B | C+ | ||
-2.69% | 11.77B | C+ | ||
+21.32% | 11.73B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRNA Stock
- Ratings Moderna, Inc.